Current status and progress of treatment for hepatocellular carcinoma with portal vein tumor thrombus

Zhang Fengbo; Zhang Chunjiao; Jiang Hongchi

doi:10.3760/cma.j.cn115610-20210302-00105

Chinese Journal of Digestive Surgery > 2021 > 20(5): 568-573. > DOI: 10.3760/cma.j.cn115610-20210302-00105

Zhang Fengbo, Zhang Chunjiao, Jiang Hongchi. Current status and progress of treatment for hepatocellular carcinoma with portal vein tumor thrombus[J]. Chinese Journal of Digestive Surgery, 2021, 20(5): 568-573. DOI: 10.3760/cma.j.cn115610-20210302-00105

Citation:

PDF

Current status and progress of treatment for hepatocellular carcinoma with portal vein tumor thrombus

Center of Hepato‑splenic Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin150001, China

Funds:

China Medical Board 08‑894

More Information

Corresponding author:
Jiang Hongchi, Email: jianghc@vip.163.com
Received Date: March 01, 2021
Available Online: July 18, 2024

Graphical Abstract

Abstract

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancers worldwide, which ranks as the second of cancer‑related death. Each year, more than half of the new and death cases occur in China. Vascular invasion is one of the important biological characteristics of HCC. HCC with portal vein tumor thrombus is closely related to the prognosis of patients, but there is no consensus on the best treatment method.Based on domestic and foreign literatures, the authors discuss the current status and progress of treatment for HCC with portal vein tumor thrombus, in order to explore the optimal treatment.
- Liver neoplasms,
- Portal vein tumor thrombus,
- Treatment,
- Current status,
- Progress

FullText(HTML)

References (53)

References

[1]	LeandroLC, ChungJ, KlassD, et al.Ablative transarterial radioembolization improves survival in patients with hcc and portal vein tumor thrombus [J].Cardiovasc Intervent Radiol,2020,43(3):411‑422.DOI:10.1007/s00270-019-02 404-5.
[2]	ZhangZM, LaiEC, ZhangC, et al. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus[J]. Int J Surg,2015,20:8‑16. DOI:10. 1016/j.ijsu.2015.05.009.
[3]	朱焕兵,李江涛.肝细胞癌合并门静脉癌栓的诊治进展[J].世界华人消化杂志,2017,25(24):2161‑2166. DOI:10.11569/ wcjd.v25.i24.2161.
[4]	WangJC, XiaAL, XuY, et al. Comprehensive treatments for hepatocellular carcinoma with portal vein tumor throm-bosis[J]. J Cell Physiol,2019,234(2):1062‑1070. DOI:10. 1002/jcp.27324.
[5]	LiuS, GuoW, ShiJ, et al. MicroRNA‑135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma[J]. J Hepatol,2012,56(2):389‑396. DOI: 10.1016/j.jhep.2011.08.008.
[6]	BerzigottiA, PiscagliaF. Ultrasound in portal hyper-tension‒part 2‒and EFSUMB recommendations for the performance and reporting of ultrasound examinations in portal hypertension[J]. Ultraschall Med,2012,33(1):8‑32; quiz 30‑31. DOI: 10.1055/s-0031-1299145.
[7]	张学文,戴朝六.肝细胞癌合并门静脉癌栓治疗现状与展望[J].临床肝胆病杂志,2019,35(4):899‑904. DOI: 10.3969/j.issn.1001-5256.2019.04.043.
[8]	Manzano‑Robleda MdelC, Barranco‑FragosoB, UribeM, et al. Portal vein thrombosis: what is new?[J]. Ann Hepatol,2015,14(1):20‑27.
[9]	ZhangXP, WangK, GuoWX, et al. Is sorafenib an optimal treatment for hepatocellular carcinoma with macrovascular invasion or metastatic disease?[J]. Hepatology,2018,68(2):786. DOI: 10.1002/hep.29862.
[10]	中国医师协会肝癌专业委员会.肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2018版)[J].中华消化外科杂志,2019,18(1):8-15. DOI:10.3760/cma.j.issn.1673-9752.2019. 01.002.
[11]	ZhangXP, WangK, WeiXB, et al. An eastern hepatobiliary surgery hospital microvascular invasion scoring system in predicting prognosis of patients with hepatocellular carcinoma and microvascular invasion after R0 liver resection: a large‑scale, multicenter study[J]. Oncologist,2019,24(12):e1476‑e1488. DOI:10.1634/theoncologist. 2018-0868.
[12]	ZhengN, WeiX, ZhangD, et al. Hepatic resection or transarterial chemoembolization for hepatocellular carci-noma with portal vein tumor thrombus[J]. Medicine (Baltimore),2016,95(26):e3959. DOI:10.1097/MD.00000 00000003959.
[13]	HatanoE, UemotoS, YamaueH, et al. Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery[J]. J Hepatobiliary Pancreat Sci,2018,25(9):395‑ 402. DOI: 10.1002/jhbp.574.
[14]	GonH, KidoM, TanakaM, et al. Growth velocity of the portal vein tumor thrombus accelerated by its progre-ssion, alpha‑fetoprotein level, and liver fibrosis stage in patients with hepatocellular carcinoma[J]. Surgery,2018, 164(5):1014‑1022. DOI: 10.1016/j.surg.2018.06.025.
[15]	ZhuangL, WenT, XuM, et al. Sorafenib combined with hepatectomy in patients with intermediate‑stage and advanced hepatocellular carcinoma[J]. Arch Med Sci,2017,13(6):1383‑1393. DOI: 10.5114/aoms.2017.71066.
[16]	HuangY, ZhangZ, ZhouY, et al. Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy?[J]. Onco Targets Ther,2019,12:541‑548. DOI: 10.2147/OTT.S187357.
[17]	ZhangXP, ChaiZT, GaoYZ, et al. Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis[J]. HPB (Oxford),2019,21(12):1687‑1696. DOI:10.1016/j.hpb. 2019.04.014.
[18]	BruixJ, RaoulJL, ShermanM, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase Ⅲ trial[J]. J Hepatol,2012,57(4):821‑829. DOI: 10.1016/j.jhep.2012.06.014.
[19]	PiscagliaF, OgasawaraS.Patient selection for transarterial chemoembolization in hepatocellular carcinoma:impor-tance of benefit/risk assessment[J].Liver Cancer,2018,7(1):104‑119. DOI: 10.1159/000485471.
[20]	ChumaM, UojimaH, HiraokaA, et al. Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupa-tion: A multicenter analysis[J]. Hepatol Res,2021,51(2):201‑215. DOI: 10.1111/hepr.13592.
[21]	BruixJ, QinS, MerleP, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double‑blind, placebo-controlled, phase 3 trial[J]. Lancet,2017,389(10064):56‑ 66. DOI: 10.1016/S0140-6736(16)32453-9.
[22]	MontalR, Andreu‑OllerC, BassaganyasL, et al. Molecular portrait of high alpha‑fetoprotein in hepatocellular carcinoma: implications for biomarker‑driven clinical trials[J]. Br J Cancer,2019,121(4):340‑343. DOI: 10.1038/s41416-019-0513-7.
[23]	El‑KhoueiryAB, SangroB, YauT, et al.Nivolumab in patients with advanced hepatocellular carcinoma (Check Mate 040): an open‑label, non‑comparative, phase1/2 dose escalation and expansion trial[J].Lancet,2017,389(10088):2492‑2502. DOI: 10.1016/S0140-6736(17)31046-2.
[24]	LarkinJ, HodiFS, WolchokJD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma[J]. N Engl J Med,2015,373(13):1270‑1271. DOI:10.1056/NEJ Mc1509660.
[25]	TsaiAK, KhanAY, WorgoCE, et al. A multikinase and DNA-PK inhibitor combination immunomodulates melanomas, suppresses tumor progression, and enhances immuno-therapies[J]. Cancer Immunol Res,2017,5(9):790‑803. DOI: 10.1158/2326-6066.CIR-17-0009.
[26]	KudoM. Immune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trials[J]. Oncology,2017,92Suppl 1:50‑62. DOI: 10.1159/000451016.
[27]	FinnRS, QinSK, IkedaM, et al.Atezolizumab plus bevaci-zumab in unresectable hepatocellular carcinoma[J].N Engl J Med,2020,382(20):1894‑1905. DOI:10.1056/NEJ Moa1915745.
[28]	GretenTF, SangroB. Targets for immunotherapy of liver cancer[J]. J Hepatol,2017,S0168-8278(17)32287-0. DOI: 10.1016/j.jhep.2017.09.007.
[29]	MaudeSL, FreyN, ShawPA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia[J]. N Engl J Med,2014,371(16):1507‑1517. DOI:10.1056/NEJ Moa1407222.
[30]	CapurroM, WanlessIR, ShermanM, et al. Glypican‑3: a novel serum and histochemical marker for hepatocellular carcinoma[J]. Gastroenterology,2003,125(1):89‑97. DOI: 10.1016/s0016-5085(03)00689-9.
[31]	Abou‑AlfaGK, PuigO, DanieleB, et al. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma[J]. J Hepatol,2016,65(2):289‑295. DOI:10.1016/j.jhep. 2016.04.004.
[32]	PanZ, DiS, ShiB, et al. Increased antitumor activities of glypican‑3‑specific chimeric antigen receptor‑modified T cells by coexpression of a soluble PD1‑CH3 fusion protein[J]. Cancer Immunol Immunother,2018,67(10):1621‑ 1634. DOI: 10.1007/s00262-018-2221-1.
[33]	WangJC, XiaAL, XuY, et al. Comprehensive treatments for hepatocellular carcinoma with portal vein tumor throm-bosis[J]. J Cell Physiol,2019,234(2):1062‑1070. DOI:10. 1002/jcp.27324.
[34]	于晓双,石娜,毛中鹏,等.经动脉化疗栓塞联合射频消融法治疗对较大原发性肝癌疗效分析[J].解放军医药杂志, 2019,31(5):30-34. DOI: 10.3969/j.issn.2095-140X.2019.05.007.
[35]	夏景林.肝癌伴肝功能不全患者的介入治疗:策略与哲学思想[J].临床误诊误治,2018,31(1):1-5. DOI:10.3969/j.issn. 1002-3429.2018.01.001.
[36]	孙军辉,周坦洋,张岳林,等.门静脉支架联合¹²⁵I粒子链植入序贯肝动脉灌注化学疗法栓塞术治疗肝癌伴门静脉癌栓[J].中华消化杂志,2014,34(1):25-29. DOI:10.3760/cma.j.issn. 0254-1432.2014.01.010.
[37]	周传力,田世超,陈晓理,等.微波消融联合经肝动脉化疗栓塞术治疗原发性肝癌合并门静脉癌栓的效果及影响因素[J].临床肝胆病杂志,2019,35(10):2220-2224. DOI:10.3969/ j.issn.1001-5256.2019.10.018.
[38]	XueTC, XieXY, ZhangL, et al. Transarterial chemoembo-lization for hepatocellular carcinoma with portal vein tumor thrombus: a meta‑analysis[J]. BMC Gastroenterol,2013,13:60. DOI: 10.1186/1471-230X-13-60.
[39]	NousoK, MiyaharaK, UchidaD, et al. Effect of hepatic arterial infusion chemotherapy of 5‑fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan[J]. Br J Cancer,2013,109(7):1904‑1907. DOI:10.1038/bjc.2013. 542.
[40]	HeM, LiQ, ZouR, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J]. JAMA Oncol,2019,5(7):953‑960. DOI: 10.1001/jamaoncol.2019.0250.
[41]	傅奎,易竹君,龚建平.原发性肝癌合并门静脉癌栓的诊断与治疗进展[J].中国现代普通外科进展,2017,20(5):413-416. DOI: 10.3969/j.issn.1009-9905.2017.05.026.
[42]	方强,汪华霖,龚建平.肝癌合并门静脉癌栓的研究进展[J].中国现代普通外科进展,2014,17(10):838-840. DOI:10. 3969/j.issn.1009-9905.2014.10.030.
[43]	曾昭冲,陈一兴.原发性肝癌放射治疗专家共识(2020年版)[J].临床肝胆病杂志,2021,37(2):296-301. DOI:10.3969/j.issn.1001-5256.2021. 02. 010.
[44]	CerritoL, AnnicchiaricoBE, IezziR, et al. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers[J]. World J Gastroenterol,2019,25(31):4360‑4382. DOI: 10.3748/wjg.v25.i31.4360.
[45]	YoonSM, RyooBY, LeeSJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radio-therapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial[J]. JAMA Oncol,2018,4(5):661‑669. DOI:10.1001/jama oncol.2017.5847.
[46]	SuF, ChenKH, LiangZG, et al. Comparison of three-dimensional conformal radiotherapy and hepatic resection in hepatocellular carcinoma with portal vein tumor thrombus[J]. Cancer Med,2018,7(9):4387‑4395. DOI:10. 1002/cam4.1708.
[47]	WeiX, JiangY, ZhangX, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepato-cellular carcinoma with portal vein tumor thrombus: a randomized, open‑label, multicenter controlled study[J]. J Clin Oncol,2019,37(24):2141‑2151. DOI:10.1200/JCO.18. 02184.
[48]	KimPH, ChoiSH, KimJH, et al. Comparison of radioembo-lization and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis: a systema-tic review and meta‑analysis of safety and efficacy[J]. Korean J Radiol,2019,20(3):385‑398. DOI:10.3348/kjr. 2018.0496.
[49]	程树群,卫旭彪.肝细胞癌伴门静脉癌栓的降期治疗[J].临床肝胆病杂志,2020,36(2):263-266. DOI:10.3969/j.issn. 1001-5256.2020.02.004.
[50]	罗文,帖君.肝癌合并门静脉高压的局部消融治疗[J].临床肝胆病杂志,2021,37(3):515-521. DOI:10.3969/j.issn. 1001- 5256.2021.03.005.
[51]	HeimbachJK, KulikLM, FinnRS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology,2018,67(1):358‑380. DOI: 10.1002/hep.29086.
[52]	中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].中华消化外科杂志,2020,19(1):1-20. DOI: 10.3760/cma.j.issn.1673-9752.2020.01.001.
[53]	樊嘉,高强.肝癌分子分型指导精准诊断与治疗的研究前沿[J].中华消化外科杂志,2020,19(1):28-31. DOI: 10.3760/cma.j.issn.1673-9752.2020.01.003.

[1]	Shen Yingmo, Liu Xiaoli, Zheng Ruotong, Tong Deyu, Ma Qiuyue. Research progress on epidemiology of inguinal hernia[J]. Chinese Journal of Digestive Surgery, 2024, 23(9): 1168-1172. DOI: 10.3760/cma.j.cn115610-20240802-00370
[2]	Mao Yihao, Feng Qingyang, Xu Jianmin. Current status and progress of robotic colorectal cancer surgery in the era of artificial intelli⁃gence[J]. Chinese Journal of Digestive Surgery, 2024, 23(4): 573-578. DOI: 10.3760/cma.j.cn115610-20240301-00139
[3]	Bai Xueli, Hong Yifan, Zhang Xiaoyu, Yang Jiaqi, Liang Tingbo. Research progress of robot‑assisted function‑preserving pancreatic surgery[J]. Chinese Journal of Digestive Surgery, 2024, 23(1): 102-108. DOI: 10.3760/cma.j.cn115610-20231226-00278
[4]	Liu Fenglin, Cai Tianyi, Gu Yangyang. Gurrent status and progress of neoadjuvant chemotherapy and conversion therapy for locally advanced gastric cancer[J]. Chinese Journal of Digestive Surgery, 2023, 22(10): 1166-1172. DOI: 10.3760/cma.j.cn115610-20230829-00040
[5]	Zhang Xinmu, Ning Cong, Zhao Haitao. Research progress in immune checkpoint inhibitors treatment of advanced biliary tract cancer[J]. Chinese Journal of Digestive Surgery, 2023, 22(7): 858-865. DOI: 10.3760/cma.j.cn115610-20230616-00290
[6]	Bian Dapeng, Feng Qiushi. Current status and progress of endoscopic drainage for acute cholecystitis[J]. Chinese Journal of Digestive Surgery, 2022, 21(7): 884-891. DOI: 10.3760/cma.j.cn115610-20220509-00261
[7]	Wang Jingyuan1, Wang Xiaojuan2, Zhang Cheng1, Qi Changsong1, Li Yanyan1, Ji Congcong1, Gao Jing1, Shen Lin1. Research progress of relationship between peritoneal microenvironment and peritoneal metastasis of gastric cancer[J]. Chinese Journal of Digestive Surgery, 2020, 19(9): 1004-1008. DOI: 10.3760/cma.j.cn115610-20200813-00547
[8]	Yang Yinmo, Zhang Zhengkui, Tian Xiaodong. Current research status and progress in molecular subty-ping of pancreatic cancer[J]. Chinese Journal of Digestive Surgery, 2019, 18(7): 616-620. DOI: 10.3760/cma.j.issn.1673-9752.2019.07.002
[9]	Liang Tingbo, Bai Xueli, Chen Wei.. Current status and progress of laparoscopic common bile duct exploration in the treatment of choledocholithiasis[J]. Chinese Journal of Digestive Surgery, 2018, 17(1): 22-25. DOI: 10.3760/cma.j.issn.1673-9752.2018.01.006
[10]	Liang Tingbo.. Research on biliary diseases: progresses and challenges[J]. Chinese Journal of Digestive Surgery, 2017, 16(1): 28-33. DOI: 10.3760/cma.j.issn.1673-9752.2017.01.006

Cited By

Get Citation

PDF

XML

Article views (1859) PDF downloads (0)

Turn off MathJax

Article Contents

Abstract

References

Current status and progress of treatment for hepatocellular carcinoma with portal vein tumor thrombus

Abstract

References

Related Articles

Catalog

Journal Info

For Authors

For Reviewers

Ethics and Policies

Archives

Special Issues

Current status and progress of treatment for hepatocellular carcinoma with portal vein tumor thrombus

Abstract

References

Related Articles

Catalog

Journal Info

For Authors

For Reviewers

Ethics and Policies

Archives

Special Issues

Export File

Citation

Format

Content